Iscalimab, an investigational antibody therapy from Novartis, showed promise for safety and preliminary efficacy for lessening disease activity in people with primary Sjögren’s syndrome who experience symptoms across the body. Larger and longer studies are warranted to assess the clinically meaningful benefits of the potential therapy, researchers…
News
Doctors should consider a diagnosis of primary Sjogren’s syndrome when faced with adolescent patients who show psychotic symptoms such as suicidal thoughts, auditory hallucinations, and paranoia, according to a case series. Titled “Adolescent Sjogren’s syndrome presenting as psychosis: a case series,” the report…
Patients with Sjögren’s syndrome and Behçet’s disease have a significantly higher risk of developing obstructive sleep apnea compared to people without those autoimmune disorders, a study has found. The study, “Risk of Obstructive Sleep Apnea in Patients with Sjögren Syndrome and Behçet’s Disease: A Nationwide, Population-Based…
The U.S. Food and Drug Administration (FDA), a vast government bureaucracy, employs about 17,500 people and had a budget of $5.7 billion in 2019. Yet even with its enormous resources, the FDA these days relies more and more on patients to…
Many people with Sjögren’s syndrome experience oral symptoms beyond mouth dryness — with trouble in speaking, oral ulcers, and difficulty swallowing identified as the ones that most impact their quality of life and finances — a study based on a U.S. patient survey has found. The study was presented…
The gleaming new Dutch headquarters of the European Medicines Agency (EMA), fronting Domenico Scarlattilaan in Amsterdam’s suburban Zuidas business district, finally opened for business last month — just over two years after the European Union decided to relocate the EMA to the Netherlands in the wake of Brexit.
A new machine learning algorithm may help identify people with primary Sjögren’s syndrome who are at an increased risk of developing non-Hodgkin’s lymphoma (NHL), a type of blood cancer, findings from a new study suggest. Using risk features such as enlarged salivary glands, counts of certain types of…
Sjogren’s syndrome is an autoimmune disease characterized by a decreased production of saliva, tears, and other secretions. A common symptom of Sjogren’s syndrome is acid reflux, also known as gastric reflux or heartburn. Sometimes, gastric reflux may progress into a more serious condition called gastroesophageal reflux…
A Phase 4 clinical trial investigating LO2A eye drops, by Wize Pharma, as a treatment for dry eye symptoms in Sjögren’s syndrome patients is fully enrolled, the company announced. Topline results from the study, taking place at multiple sites in Israel, are expected by August. They will be used to…
LOU064, an inhibitor of the Bruton tyrosine kinase (BTK) protein, is able to reduce the activation of B-cells both in lab dishes and in animal models, suggesting it has therapeutic potential in diseases such as Sjögren’s syndrome, a study shows. These findings were further confirmed in healthy volunteers,…
Recent Posts
- Childhood-onset Sjögren’s can cause lasting damage to organs: Study
- Salivary duct treatment eases dry mouth in Sjögren’s disease: Study
- 4 genes linked to inflammatory cell death very active in Sjögren’s
- AI can see what doctors miss to accurately diagnose Sjögren’s
- Worse fatigue tied to more pain in people with Sjögren’s, study finds
- Dazodalibep therapy now in Phase 3 testing for Sjögren’s disease
- Sjögren’s treatment ianalumab shows rapid disease relief in trials
- Sjögren’s patients on nipocalimab report less pain, dryness in trial
- Ouro starts Phase 1b trial of OM336 for Sjögren’s disease treatment
- Telitacicept eases Sjögren’s disease activity in Phase 3 trial